These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


819 related items for PubMed ID: 26629541

  • 41. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
    Tuyishime M, Garrido C, Jha S, Moeser M, Mielke D, LaBranche C, Montefiori D, Haynes BF, Joseph S, Margolis DM, Ferrari G.
    J Clin Invest; 2020 Oct 01; 130(10):5157-5170. PubMed ID: 32584790
    [Abstract] [Full Text] [Related]

  • 42. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals.
    Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, Bernard N, Tremblay C, Kaufmann DE, Roger M, Finzi A.
    J Virol; 2015 Jan 01; 89(1):545-51. PubMed ID: 25339767
    [Abstract] [Full Text] [Related]

  • 43. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T, Kurth R, Norley S.
    J Immunol; 1994 Aug 15; 153(4):1895-904. PubMed ID: 7519220
    [Abstract] [Full Text] [Related]

  • 44. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
    Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Kärre K, Kent SJ, Berg L.
    Viral Immunol; 2011 Oct 15; 24(5):359-68. PubMed ID: 21958370
    [Abstract] [Full Text] [Related]

  • 45. Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?
    Lee WS, Kent SJ.
    Curr Opin HIV AIDS; 2018 Mar 15; 13(2):160-166. PubMed ID: 29194123
    [Abstract] [Full Text] [Related]

  • 46. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
    Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE.
    PLoS One; 2018 Mar 15; 13(12):e0209437. PubMed ID: 30566528
    [Abstract] [Full Text] [Related]

  • 47. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.
    Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC.
    PLoS One; 2011 Mar 15; 6(9):e24078. PubMed ID: 21931643
    [Abstract] [Full Text] [Related]

  • 48. Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates.
    Ding S, Verly MM, Princiotto A, Melillo B, Moody AM, Bradley T, Easterhoff D, Roger M, Hahn BH, Madani N, Smith AB, Haynes BF, Sodroski J, Finzi A.
    AIDS Res Hum Retroviruses; 2017 May 15; 33(5):428-431. PubMed ID: 27846736
    [Abstract] [Full Text] [Related]

  • 49. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.
    Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W.
    AIDS Res Hum Retroviruses; 2012 Oct 15; 28(10):1250-8. PubMed ID: 22288892
    [Abstract] [Full Text] [Related]

  • 50. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.
    J Immunol; 2016 Apr 01; 196(7):3064-78. PubMed ID: 26944928
    [Abstract] [Full Text] [Related]

  • 51. The Early Antibody-Dependent Cell-Mediated Cytotoxicity Response Is Associated With Lower Viral Set Point in Individuals With Primary HIV Infection.
    Chen X, Lin M, Qian S, Zhang Z, Fu Y, Xu J, Han X, Ding H, Dong T, Shang H, Jiang Y.
    Front Immunol; 2018 Apr 01; 9():2322. PubMed ID: 30356637
    [Abstract] [Full Text] [Related]

  • 52. Beyond Viral Neutralization.
    Lewis GK, Pazgier M, Evans DT, Ferrari G, Bournazos S, Parsons MS, Bernard NF, Finzi A.
    AIDS Res Hum Retroviruses; 2017 Aug 01; 33(8):760-764. PubMed ID: 28084796
    [Abstract] [Full Text] [Related]

  • 53. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR.
    J Virol; 2015 Mar 01; 89(5):2659-71. PubMed ID: 25520506
    [Abstract] [Full Text] [Related]

  • 54. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
    Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H, Apps R, Goldstein H, Lynch RM, Jones RB.
    J Virol; 2018 Dec 01; 92(23):. PubMed ID: 30209173
    [Abstract] [Full Text] [Related]

  • 55. Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity.
    Kim JS, Nag P, Landay AL, Alves M, Cohn MH, Bremer JW, Baum LL.
    FEMS Immunol Med Microbiol; 2006 Nov 01; 48(2):267-73. PubMed ID: 16978244
    [Abstract] [Full Text] [Related]

  • 56. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z, Li J, Hu X, Shao Y, Zhang MY.
    Antiviral Res; 2015 Jun 01; 118():1-9. PubMed ID: 25770672
    [Abstract] [Full Text] [Related]

  • 57. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
    Gorny MK, Mascola JR, Israel ZR, VanCott TC, Williams C, Balfe P, Hioe C, Brodine S, Burda S, Zolla-Pazner S.
    AIDS Res Hum Retroviruses; 1998 Feb 10; 14(3):213-21. PubMed ID: 9491911
    [Abstract] [Full Text] [Related]

  • 58. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
    Hessell AJ, McBurney S, Pandey S, Sutton W, Liu L, Li L, Totrov M, Zolla-Pazner S, Haigwood NL, Gorny MK.
    Vaccine; 2016 May 23; 34(24):2713-21. PubMed ID: 27102818
    [Abstract] [Full Text] [Related]

  • 59. Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
    Kumar S, Batra H, Singh S, Chawla H, Singh R, Katpara S, Hussain AW, Das BK, Lodha R, Kabra SK, Luthra K.
    J Gen Virol; 2020 Dec 23; 101(12):1289-1299. PubMed ID: 32915123
    [Abstract] [Full Text] [Related]

  • 60. Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial.
    McLean MR, Madhavi V, Wines BD, Hogarth PM, Chung AW, Kent SJ.
    J Immunol; 2017 Jul 15; 199(2):816-826. PubMed ID: 28615419
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 41.